Recent advance in influencing factors of non-response to Infliximab therapy in children with inflammatory bowel disease / 中国小儿急救医学
Chinese Pediatric Emergency Medicine
; (12): 208-211, 2023.
Article
in Zh
| WPRIM
| ID: wpr-990504
Responsible library:
WPRO
ABSTRACT
Inflammatory bowel disease(IBD)is a group chronic inflammatory gastrointestinal diseases with unknown etiology, which includes Crohn′s disease, ulcerative colitis and indeterminate colitis.The number of pediatric IBD patients increases year by year and the disease causes a huge burden on patients, families and society.Infliximab(IFX) is an effective and important drug, but more and more patients don′t respense to it.The reason for non-respense is complex and unclear.This review discussed the factors that may cause failure to respond to IFX, in order to find a suitable method to improve the therapeutic effect of IFX on children with IBD.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Chinese Pediatric Emergency Medicine
Year:
2023
Type:
Article